Breaking News

Romark Awarded HHS Influenza Contract

March 1, 2013

To complete development of NT-300

Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the development of NT-300 (nitazoxanide) for acute uncomplicated influenza. The contract, valued at $44 million, will be administered through the Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response.
 
BARDA selected Romark for its development plan that includes a novel mechanism of action targeting host factors with the potential for broad-spectrum antiviral activity. NT-300 is administered orally, and it is being proposed for treatment of seasonal as well as pandemic influenza.
 
Romark will provide non-clinical and clinical development, as well as regulatory activities required to submit and manage the NDA. Romark's Phase III trial will evaluate the efficacy and safety of NT-300 or NT-300 plus oseltamivir compared to a placebo or to oseltamivir alone in treating outpatients with acute uncomplicated influenza.
 
"There is a pressing need for new drugs to treat influenza," said Jean-Francois Rossignol, M.D., Ph.D., chairman and chief science officer of Romark. "BARDA plays an important role in the advanced development of new countermeasures for public health threats such as pandemic influenza, and we are pleased to have the opportunity to work with them."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016